279 related articles for article (PubMed ID: 8298943)
1. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis.
Nugent KP; Farmer KC; Spigelman AD; Williams CB; Phillips RK
Br J Surg; 1993 Dec; 80(12):1618-9. PubMed ID: 8298943
[TBL] [Abstract][Full Text] [Related]
2. Effect of sulindac on small polyps in familial adenomatous polyposis.
Debinski HS; Trojan J; Nugent KP; Spigelman AD; Phillips RK
Lancet; 1995 Apr; 345(8953):855-6. PubMed ID: 7898240
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
4. Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polyps in familial adenomatous polyposis.
Seow-Choen F; Vijayan V; Keng V
Br J Surg; 1996 Dec; 83(12):1763-6. PubMed ID: 9038563
[TBL] [Abstract][Full Text] [Related]
5. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment.
Spagnesi MT; Tonelli F; Dolara P; Caderni G; Valanzano R; Anastasi A; Bianchini F
Gastroenterology; 1994 Feb; 106(2):362-6. PubMed ID: 8299902
[TBL] [Abstract][Full Text] [Related]
6. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.
Giardiello FM; Hamilton SR; Krush AJ; Piantadosi S; Hylind LM; Celano P; Booker SV; Robinson CR; Offerhaus GJ
N Engl J Med; 1993 May; 328(18):1313-6. PubMed ID: 8385741
[TBL] [Abstract][Full Text] [Related]
7. Sulindac causes regression of rectal polyps in familial adenomatous polyposis.
Labayle D; Fischer D; Vielh P; Drouhin F; Pariente A; Bories C; Duhamel O; Trousset M; Attali P
Gastroenterology; 1991 Sep; 101(3):635-9. PubMed ID: 1650315
[TBL] [Abstract][Full Text] [Related]
8. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis.
Winde G; Schmid KW; Brandt B; Müller O; Osswald H
Dis Colon Rectum; 1997 Oct; 40(10):1156-68; discussion 1168-9. PubMed ID: 9336110
[TBL] [Abstract][Full Text] [Related]
9. Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial.
Samadder NJ; Neklason DW; Boucher KM; Byrne KR; Kanth P; Samowitz W; Jones D; Tavtigian SV; Done MW; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Davis R; Topham MK; Lynch P; Strait E; McKinnon W; Burt RW; Kuwada SK
JAMA; 2016 Mar 22-29; 315(12):1266-75. PubMed ID: 27002448
[TBL] [Abstract][Full Text] [Related]
10. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy.
Niv Y; Fraser GM
Gastroenterology; 1994 Sep; 107(3):854-7. PubMed ID: 8076772
[TBL] [Abstract][Full Text] [Related]
11. [Role of suindac in the treatment of familial adenomatous polyposis coli].
Landauer S; Halimi C; Caulin C; Bergmann JF
Therapie; 1999; 54(6):675-82. PubMed ID: 10709439
[TBL] [Abstract][Full Text] [Related]
12. Sulindac for periampullary polyps in FAP patients.
Richard CS; Berk T; Bapat BV; Haber G; Cohen Z; Gallinger S
Int J Colorectal Dis; 1997; 12(1):14-8. PubMed ID: 9112144
[TBL] [Abstract][Full Text] [Related]
13. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
Samadder NJ; Kuwada SK; Boucher KM; Byrne K; Kanth P; Samowitz W; Jones D; Tavtigian SV; Westover M; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Burt RW; Neklason DW
JAMA Oncol; 2018 May; 4(5):671-677. PubMed ID: 29423501
[TBL] [Abstract][Full Text] [Related]
14. [Treatment with sulindac of adenomatous polyps in familial polyposis].
Cerdán FJ; Torres-Melero J; Martínez S; Gutiérrez del Olmo A; Balibrea JL
Rev Esp Enferm Dig; 1995 Aug; 87(8):574-6. PubMed ID: 7577106
[TBL] [Abstract][Full Text] [Related]
15. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac.
Keller JJ; Offerhaus GJ; Polak M; Goodman SN; Zahurak ML; Hylind LM; Hamilton SR; Giardiello FM
Gut; 1999 Dec; 45(6):822-8. PubMed ID: 10562579
[TBL] [Abstract][Full Text] [Related]
16. Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.
van Heumen BW; Roelofs HM; Vink-Börger ME; Dekker E; Mathus-Vliegen EM; Dees J; Koornstra JJ; Langers AM; Nagtegaal ID; Kampman E; Peters WH; Nagengast FM
Orphanet J Rare Dis; 2013 Aug; 8():118. PubMed ID: 23919274
[TBL] [Abstract][Full Text] [Related]
17. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months.
Winde G; Schmid KW; Schlegel W; Fischer R; Osswald H; Bünte H
Dis Colon Rectum; 1995 Aug; 38(8):813-30. PubMed ID: 7634976
[TBL] [Abstract][Full Text] [Related]
18. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis.
Pasricha PJ; Bedi A; O'Connor K; Rashid A; Akhtar AJ; Zahurak ML; Piantadosi S; Hamilton SR; Giardiello FM
Gastroenterology; 1995 Sep; 109(3):994-8. PubMed ID: 7657130
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.
Cruz-Correa M; Hylind LM; Romans KE; Booker SV; Giardiello FM
Gastroenterology; 2002 Mar; 122(3):641-5. PubMed ID: 11874996
[TBL] [Abstract][Full Text] [Related]
20. Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis.
Burke CA; Dekker E; Lynch P; Samadder NJ; Balaguer F; Hüneburg R; Burn J; Castells A; Gallinger S; Lim R; Stoffel EM; Gupta S; Henderson A; Kallenberg FG; Kanth P; Roos VH; Ginsberg GG; Sinicrope FA; Strassburg CP; Van Cutsem E; Church J; Lalloo F; Willingham FF; Wise PE; Grady WM; Ford M; Weiss JM; Gryfe R; Rustgi AK; Syngal S; Cohen A
N Engl J Med; 2020 Sep; 383(11):1028-1039. PubMed ID: 32905675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
